What are the precautions for Olaparib?

During treatment with Olaparib, patients should pay attention to the occurrence of myelodysplastic syndrome/acute myeloid leukemia, pneumonia, venous thromboembolism, embryo-fetal toxicity and other events.

1. Myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML):

In clinical studies, the cumulative incidence of olaparib as a single agent was approximately 1.5%, and all of these patients had previously received chemotherapy with platinum-based drugs and/or other DNA-damaging agents, including radiotherapy. Do not initiate olaparib until the patient has recovered from hematologic toxicity (≤Grade 1) caused by prior chemotherapy. Monitor complete blood counts for cytopenias at baseline and for clinically significant changes monthly during treatment. For long-term hematologic toxicity, interrupt olaparib and monitor blood counts weekly until recovery. If levels do not return to grade 1 or less after 4 weeks, discontinue olaparib and initiate treatment aggressively.

2. Pneumonia:

In clinical studies, the incidence of pneumonia (including deaths) in patients receiving olaparib as a single agent was 0.8%. If a patient develops new or worsening respiratory symptoms, such as dyspnea, cough, and fever, or develops radiological abnormalities, olaparib treatment should be interrupted and the source of symptoms evaluated immediately. If pneumonia is confirmed, discontinue olaparib treatment and treat the patient appropriately.

3、静脉血栓栓塞（VTE）：

Venous thromboembolism, including severe or fatal pulmonary embolism (PE), has occurred in patients receiving olaparib. In combined data from two randomized, placebo-controlled clinical studies (deep and PROpel) in patients with metastatic castration-resistant prostate cancer, VTE occurred in 8% of patients treated with olaparib, including pulmonary embolism in 6%. Monitor patients for clinical signs and symptoms of venous thrombosis and pulmonary embolism and institute appropriate medical treatment, including long-term anticoagulation as clinically indicated.

4. Embryo-Fetotoxicity:

Based on olaparib's mechanism of action and findings in animals, when olaparib is given to pregnant womenmay cause harm to the fetus. In an animal reproduction study, administration of olaparib to pregnant rats during organogenesis resulted in less teratogenic and embryo-fetal toxicity than in patients receiving the recommended human dose of 300 mg twice daily. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose of olaparib. Based on the results of genotoxicity and animal reproduction studies, it is recommended that male patients with a female partner of reproductive potential or who are pregnant use effective contraception during treatment and for 3 months after the last dose of olaparib.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.